NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-
testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit …

Tumour-specific antigens have been an area of interest in cancer therapy since their
discovery in the middle of the 20th century. In the era of immune-based cancer therapeutics …

Immune-based therapies for cancer are generating substantial interest because of the
success of immune checkpoint inhibitors. This study aimed to enhance anticancer immunity …

Generating responses to tumor antigens poses a challenge for immunotherapy. This phase
II trial (NCT02129075) tested fms-like tyrosine kinase 3 (Flt3) ligand pre-treatment …

Antigen-specific immunotherapy was studied in a multi-institutional phase 1/2 study by
combining decitabine (DAC) followed by an autologous dendritic cell (DC)/MAGE-A1, MAGE …

The development of cancer vaccines has been intensively pursued over the past 50 years
with modest success. However, recent advancements in the fields of genetics, molecular …

Abstract Introduction Cancer Immunotherapy has recently emerged as a promising and
effective modality to treat different malignancies. Antigenic profiling of cancer tissues and …

Bladder cancer is the most common malignancy of the urinary tract, presents the highest
recurrence rate among solid tumors and is the second leading cause of death in …

Azanucleoside DNA-hypomethylating agents have remarkable clinical activity in
myelodysplastic syndromes and acute myeloid leukemia (AML), particularly at low, non …

Myxoid and round-cell liposarcoma is a frequently encountered liposarcoma subtype. The
mainstay of treatment remains surgical excision with or without chemoradiation. However …